Read the latest news from EMVO

EMVO marks the 4th anniversary of EMVS
The European Medicines Verification System (EMVS) celebrates its 4th anniversary on February 9, 2023.
Along with all NMVOs, this was marked. Read more about the last 4 years of work with FMD, and statements from EMVOs General Manager Andreas Walther, and DMVOs Director Tina Hou Marer here.

EAMS "Go-live"
EMVO is launching EAMS, the European Alert Management System, and connection is possible for OBPs and NMVOs on 9th of February, 2023 and onwards.
Read more about it here.

EMVO notice update of OBP Divestiture & Acquisition (D&A) Guide.For more see here.

EMVO sends out 2022 holiday bulletin. For more see here.

EMVO informes about renewal EU Hub certificates and alert points. For more see here.

EMVO informes about whitelist additional EU Hub IP adresses in your firewall. For more see here.

EMVO celebrates the EMVS third anniversary on February 9th 2022. For more see here.

Mandatory conformity to Transport Layer Security (TLS) 1.2 or higher. To ensure the security of the EMVS, EMVO would like to inform you that when the EU Hub Release 1.10 will be deployed in IQE and PRD by the end of the year, it will no longer accept connections with Transport Layer Security (TLS) versions prior to 1.2. For more, pls. see here

Webcast Series Launch – EU FMD Designated Wholesaler Webcast Series. EMVO is announcing the launch of the EMVO Webcast series – a series of remote trainings and webcasts aimed at providing you with useful information on a diverse set of topics related to the EMVS. The recording is accessible here and on EMVO’s website (Knowledge Database  -> Videos).

EMVO is regularly monitoring the EMVS security infrastructure to protect it from
cyber security hazards. A disruptive test will be executed on the EU Hub in the Integrated Quality Environment (IQE) on the following dates:
29th June from 10:00 CEST to 18:30 CEST
30th June from 10:00 CEST to 18:30 CEST
1st July from 10:00 CEST to 18:30 CEST

EMVO informs you that the Guideline on "Best Practice on Alert Handling" has been approved by EMVO´s Board and is now available here

EMVO communicates about decommissioning of products: use of correct statuses. For more see here

EMVO communicates about the next update on the Hub release 1.9. 
For more see here

EMVO communicates about the Alert Management System (AMS) project, which ultimate goal is to maximise the efficiency of alert management in the EMVS. See more here

EMVO has updated the Brexit "Q&A" article, which outlines frequently asked questions regarding Brexit. For more pls. see here

EMVO has created a guide describing how Covid-19 vaccines are handled in the national systems. For more, kindly see here

EMVO has developed a description on how to investigate Intermarket Transactions. For more, pls. see here

Letter of Announcement from EMVO
EMVO has been working to manage the implications of Brexit (the UK’s departure from the EU Internal Market rules) for the EMVS and its users. This was undertaken in close collaboration with concerned authorities and stakeholders, including the European Commission, as well as the most impacted National Medicines Verification Organisations (NMVOs). Although the final Brexit negotiations continue, EMVO is working to ensure that as from 1 January 2021 the operation of the EMVS is adapted to the EU-UK Withdrawal Agreement and Northern Ireland Protocol (included as an Annex thereto) that makes certain provisions of EU law applicable “to and in the United Kingdom in respect of Northern Ireland”. Read more here

Letter of Announcement from EMVO
EMVO has developed a cross-departmental strategy to ensure that the relevant information is provided to all OBPs and Stakeholders promptly. We have created a Communication Matrix to streamline our internal workflows to allow the right teams to react quickly to future situations. Read more here

Letter of announcement from EMVO
Based on a new system improvement to the EU Hub, EMVO would like to advise you to whitelist the following IP addresses in your network (and internal firewall) settings. The benefit of this update is that Outbound IP addresses (Hub to OBP) for the different environments (ITE, IQE and PRD) will become static, meaning they will never change. We strongly recommend that you update your whitelist and firewall settings as soon as possible. Read more here

Letter of announcement from EMVO
Regarding the recent EU Hub outage, EMVO plan to keep you informed regularly as they progress with the root cause analysis process. Read more here

Letter of announcement from EMVO
Withdrawal of a product code (SKU) affects all packs of all batches in the transaction specified markets. The status “Withdrawn” prevents the uploading of additional batches to the system for the affected markets. Additionally, the end-user of the affected markets will not be able to decommission the packs in the EMVS. EMVO would like to remind once more that the withdrawal of data and batch recall within the EMVS are irreversible actions. For more pls. see here

Letter of announcement from EMVO
EMVO took the decision to allow its employees to work remotely, from home, until further notice. EMVO will ensure that its support and assistance to OBPs will be provided as far as possible.  Please note that the usual channel of communication remains at your disposal: Email: EMVO Helpdesk  Phone: +32 (0)2 657 00 08 
This measure is taken by EMVO and does not bind any National Medicines Verification Organisation (NMVO). In order to know the applicable measures per country, please consult the relevant NMVO.  

EMVO has released a new version of frequently-asked 'questions and answers' regarding the implementation of the rules on the safety features for medicinal products for human use. For more pls. see here

Letter of announcement from EMVO
EMVO has created a document to provide further information on how versioning and the retrospective data upload work.  For more pls. see here

Letter of announcement from EMVO
EMVO would like to provide you with additional information related to the next EU Hub Release 1.7 and the allocated testing period. Please note that three weeks will be granted for testing in the IQE environment, planned to start end of March/ early April 2020. For more pls. see here

Letter of announcement from EMVO
EMVO would like to inform you that the latest update of the Fee Models overview of NMVOs has been published on the EMVO website. For more pls. see here

Letter of announcement from EMVO
The 2016 schema of the OBP Interface will no longer be supported as of EU Hub release 1.7 planned for mid-April 2020.  If you are still using the 2016 schema, please switch to the 2018 schema before mid-April 2020 in order to be able to remain connected to the EU Hub. For more pls. see here

Letter of announcement from EMVO
New contact number for EMVO Helpdesk will be activated: +32 2 657 00 08. For more see here

Letter of announcement from EMVO
It has been noted that a number of end user systems are misconfigured and are not correctly announcing that the data has been entered manually. For more pls. see here

Letter of annoucement from EMVO
EMVO would like to announce that Release 1.6.02 of the EU Hub was successfully deployed to the Production Environment (PRD) on Saturday 2nd November.  For more pls. see here

Letter of announcement from EMVO
Due to the need to undertake maintenance and renew an SSL certificate, there will be a downtime of the EMVO Gateway PRD for approximately 3 hours on Friday 8th November. The downtime will begin at 5pm (CET). For more, pls. see here

Letter of announcement from EMVO
EMVO has been informed about a large number of alerts currently being caused due to incorrect actions in the event of a batch recall.
According to Article 40 (c) of the Delegated Regulation (EU) 2016/161, a batch recall must be reflected within the EMVS. (EU Hub and National Systems). For more, pls. see here

Letter of announcement from EMVO
EMVO would like to remind OBPs that for Multi-Market Packs (MMPs), the master, batch and pack data must be loaded to all of the markets within the defined cluster, i.e. for all markets to which the MMP can be distributed. See more here

EMVO Newsletter
A new medicines safety verification system has been successfully implemented in Latvia. There are almost 40 million active packs in the Latvian repository. For more, pls. see here

Letter of announcement from EMVO
In order to reduce the number of alerts, EMVO recommends that wholesalers verify one pack per batch (released after 9th February) upon receipt. For more, pls. see here

Letter of announcement from EMVO
EMVO is aware that some OBPs investigate alerts by verifying a Unique Identifier (UI) to better understand the root cause of an alert. The action of performing individual pack verification for alert investigation purposes is considered as an acceptable divergence from the general statement regarding the pack being ‘at hand’. Read more here

Letter of announcement from EMVO
EMVO can now officially announce Release 1.6 of the EU Hub, which is planned to be available in IQE in mid-October, and in PRD in mid-November. The new realease will bring new functionalities. For more, pls. see here

Letter of announcement from EMVO
Since the latest release of the national systems  in July, OBPs are receiving alert messages in a new format. During calendar week 36 this new format will also be sent from the national systems of FI and ES. For more see here

EMVO Newsletter
Katriina NewtonKolehmainen, Communications Assistant at FimVO, the Finnish Medicines Verification Organisation who shares with us an insight the situation on Finland. Read more here

Q&A V.15.0 - Safety Features for Medical Products for human use
The European Commision has published  an updated version of  Q&As. For more see here

Letter of announcement from EMVO
EU Hub Release 1.5 has now been deployed in the IQE environment. EMVO recommends that all OBPs conduct IQE testing  - preferably before the 25th of July - to ensure that all call-backs are correctly received from these national systems. More info here

EMVO Newsletter
This week´s NMVO contribution comes from Mitja Pirman, managing director at ZAPAZ, the Slovenian medicines verification organisation, who gives an insight into the situation in Slovenia. Read more here.

EMVO Newsletter
In this week´s letter, insights have been provided by Nadine Bourg & Claude Farrugia from MaMVO, who give an overview of the FMD implementation in Malta. Read more here.

Letter of Announcement from EMVO
This communication provides clear guidance on subscripting to notifications for national systems from the European Medicines Verification System Information (EVI) tool on the EMVO website.

Letter of Announcement from EMVO
The intention of the communication is to provide clear guidance for the completion of Product Master Data that Parallel Distributors must undertake in order to be compliant as errors have been uncovered by EMVO. Read more here. 

EMVO Newsletter
Leonie Clarke, the General Manager of MVO Ireland, gives an insight to the situation in Ireland. Read more here.

EMVO Newsletter
Ricardo Valente, the General Manager of MVO Portugal, gives an insight to the situation in Portugal. Read more here.

EMVO Newsletter
This week, Kristina von Sydow, General Manager of e-VIS, provides an update on FMD implementation in Sweden. Read more here.

Released: EMVO bi-weekly newsletter
EMVO is pleased to announce that from this April onwards, EMVO will be issuing a newsletter every two weeks informing you about the activities of EMVO. Read more here.

Letter of Announcement from EMVO
All OBPs must ensure that the representation of the expiry date in the Data Matrix Code printed upon the pack is identical to that which is loaded to the EMVS via the EU Hub. Read more here.

Letter of Announcement from EMVO
EMVO advises all OBPs to directly contact the relevant NMVO when they experience an alert which they suspect is related to End-User software or scanner misconfiguration. Read more here.

​For more information pls. see